Effect of resveratrol administration on metabolic syndrome, insulin sensitivity, and insulin secretion

Metabolic Syndrome and Related Disorders

Volumn 12, Issue 10, 2014, Pages 497-501

  Méndez Del Villar, Miriam ^a   González Ortiz, Manuel ^a   Martínez Abundis, Esperanza ^a   Pérez Rubio, Karina G ^a   Lizárraga Valdez, Roberto ^a  

^a UNIVERSITY OF GUADALAJARA   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; PLACEBO; RESVERATROL; TRIACYLGLYCEROL; BIOLOGICAL MARKER; GLUCOSE BLOOD LEVEL; STILBENE DERIVATIVE;

ADULT; ARTICLE; BODY MASS; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; EVALUATION STUDY; FAT MASS; FEMALE; HUMAN; INSULIN RELEASE; INSULIN SENSITIVITY; MALE; METABOLIC SYNDROME X; RANDOMIZED CONTROLLED TRIAL; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; AREA UNDER THE CURVE; BLOOD; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; HYPERINSULINISM; INSULIN RESISTANCE; METABOLISM; MEXICO; MIDDLE AGED; OBESITY; PREDICTIVE VALUE; TIME; TREATMENT OUTCOME; WEIGHT REDUCTION;

ADIPOSITY; ADULT; AREA UNDER CURVE; BIOLOGICAL MARKERS; BLOOD GLUCOSE; BODY MASS INDEX; CHOLESTEROL, HDL; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPERINSULINISM; INSULIN; INSULIN RESISTANCE; MALE; METABOLIC SYNDROME X; MEXICO; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; STILBENES; TIME FACTORS; TREATMENT OUTCOME; TRIGLYCERIDES; WEIGHT LOSS;

EID: 84911393595     PISSN: 15404196     EISSN: 15578518     Source Type: Journal    
DOI: 10.1089/met.2014.0082     Document Type: Article

References (25)

1. González-Ortiz M, Martñez-Abundis E, Jacques-Camarena O, et al. Prevalence of metabolic syndrome in adults with excess of adiposity: Comparison of the Adult Treatment Panel III criteria with the International Diabetes Federation definition. Acta Diabetol 2006;43:84-86.
2. Pineda CA. Sñdrome metabólico: Definición, historia, criterios. Colomb Med 2008;39:96-106.
3. International Diabetes Federation. The IDF consensus worldwide definition of the metabolic syndrome. 1st International Congress of Prediabetes and the Metabolic Syndrome: Epidemiology, management and prevention of diabetes and cardiovascular disease, April 24, 2009, Berlin, Germany
4. Catalog B, Batriel S, Taga Y, et al. Resveratrol: French paradox revisited. Front Pharmacol 2012;3:1-18.
5. Wang S, Moustaid-Moussa N, Chen L, et al. Novel insights of dietary polyphenols and obesity. J Nutr Biochem 2014; 25:1-18.
6. Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: Comparison with the euglycemic insulin clamp. Diabetes Care 1999;22: 1462-1470.
7. Stumvoll M, Mitrakou A, Pimienta W, et al. Use of the oral glucose tolerance test to assess insulin release and insulin sensitivity. Diabetes Care 2000;23:295-301.
8. Jeyaseelan L, Rao PSS. Methods of determining sample sizes in clinical trials. Indian J Pediatr 1989;26:115-121.
9. Ramrez-Vargas E, Arnaud-Viñas MR, Delisle H. Prevalence of the metabolic syndrome and associated lifestyles in adult males from Oaxaca, Mexico. Salud Publica Mex 2007;49:94-102.
10. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005;365:1415-1428.
11. Affuso F, Mercurio V, Ruvolo A, et al. A nutraceutical combination improves insulin sensitivity in patients with metabolic syndrome. World J Cardiol 2012;26:77-83.
12. Allard JS, Perez E, Zou S, et al. Dietary activators of Sirt1. Mol Cell Endocrinol 2009;299:58-63.
13. De Kreutzenberg SV, Ceolotto G, Papparella I, et al. Downregulation of the longevity-Associated protein sirtuin 1 in insulin resistance and metabolic syndrome: Potential biochemical mechanisms. Diabetes 2010;59:1006-1015.
14. Picard F, Kurtev M, Chung N, et al. Sirt1 promotes fat mobilization in white adipocytes by repressing PPARgamma. Nature 2004;429:771-776.
15. Baur JA. Resveratrol, sirtuins, and the promise of a DR mimetic. Mech Ageing Dev 2010;131:261-269.
16. Baur JA, Pearson JK, Price NL, et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature 2006;444:337-342.
17. Beaudeux JL, Nivet-Antonie V, Giral P. Resveratrol: A relevant pharmacological approach for the treatment of metabolic syndrome?. Curr Opin Clin Nutr Metab Care 2010;6:729-736.
18. Fischer-Posovsky P, Kikulus V, Tews D, et al. Resveratrol regulates human adipocyte number and function in a Sirt1-dependent manner. Am J Clin Nutr 2010;92:5-15.
19. Timers S, Konings E, Bilet L, et al. Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell Metab 2011;14:612-622.
20. Poulsen MM, Vestergaard PF, Clasen BF, et al. High-dose resveratrol supplementation in obese men: An investigatorinitiated, randomized, placebo-controlled clinical trial of substrate metabolism, insulin sensitivity, and body composition. Diabetes 2013;62:1186-1195.
21. Um JH, Park SJ, Kang H, et al. AMP-Activated protein kinase-deficient mice are resistant to the metabolic effects of resveratrol. Diabetes 2010;59:554-563.
22. Skrobuk P, von Kraemer S, Semenova MM, et al. Acute exposure to resveratrol inhibits AMPK activity in human skeletal muscle cells. Diabetologia 2012;55:3051-3060.
23. Szkudelski T. Resveratrol-induced inhibition of insulin secretion from rat pancreatic islets: Evidence for pivotal role of metabolic disturbances. Am J Physiol Endocrinol Metab 2007;293:E901-E907.
24. Szkudelski T, Szkudelska K. Anti-diabetic effects of resveratrol. Ann NY Acad Sci 2011;1215:34-39.
25. Liu K, Zhou R, Wang B, et al. Effect of resveratrol on glucose control and insulin sensitivity: A meta-Analysis of 11 randomized controlled trials. Am J Clin Nutr 2014;99: 1510-1519.